Synthesis of cyclic imide containing peptide products

Patent metadata

Field	Value
Publication number	US-10450343-B2
Application number	US-201414778502-A
Country	US
Kind code	B2
Filing date	Mar 19, 2014
Priority date	Mar 21, 2013
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

The present invention relates to a method of synthesizing a peptide product comprising at least one cyclic imide group. Further, the invention relates to a peptide product comprising at least one cyclic imide group, which is substantially free from degradation products. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of a GLP-1 agonist like exendin peptides.

First claim

The invention claimed is:

1. A method of synthesizing a peptide product comprising at least one cyclic imide group of formula (I) or a salt or solvate thereof:

wherein
R 1 is a bridge of one or two atoms lengths,
R 2 is an amino acid side chain,
* denotes an asymmetric C atom, and
(*) denotes an optionally asymmetric C atom, comprising the steps:

(a) coupling a synthesis building block of formula (II):

wherein
X is a base-labile amino protecting group,
Y is an unprotected carboxy or carboxamido group,
* denotes an asymmetric C atom, and
Z is a carboxy group,

to a peptide product of formula (III)

wherein
R 2 is an optionally protected amino acid side chain,
R 3 is a peptidic residue bound to a solid phase carrier, and
(*) denotes an optionally asymmetric C atom under conditions wherein the cyclic imide group of formula (I) is formed,

(b) cleaving off the amino protecting group X,
(c) optionally continuing the peptide synthesis, and
(d) optionally purifying the peptide product (I).

2. The method of claim 1 , wherein R 1 is —CH 2 —.

3. The method of claim 1 , wherein R 1 is —CH 2 —CH 2 —.

4. The method of claim 1 , wherein Y is a carboxy group.

5. The method of claim 1 , wherein Y is a carboxamido group.

6. The method of claim 1 , wherein X is an Fmoc amino protecting group.

7. The method of claim 1 , wherein the solid phase carrier is a resin.

8. The method of claim 1 , wherein the coupling conditions in step (a) comprise a reaction time of at least 12 h, a temperature of between 15 and 40° C.

9. The method of claim 1 , wherein the coupling conditions in step (a) comprise dimethylformamide (DMF) as organic solvent.

10. The method of claim 1 , wherein the yield of a cyclic imide product in coupling step (a) is >50% based on the amount of the total yield of a coupling product in step (a).

11. The method of claim 1 , wherein cleaving step (b) is carried out with a deprotecting agent selected from 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).

12. The method of claim 1 , wherein the cyclic imide group of formula (I) is selectively introduced at least one predetermined position of the peptide product.

13. The method of claim 8 , further comprising repeated addition of coupling reagents, wherein the coupling agents are selected from O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), (2-(1H-benzotriazole-1-yl),1,1,3,3-tetramethyluronium) hexafluorophosphate (HBTU) with diisopropylethylamine (DIPEA), and 1-hydroxybenzotriazole/diisopropylcarbodiimide (HOBt/DIC).

14. The method of claim 1 , wherein the least one cyclic imide group of formula (I) is at position Asp(9) of the peptide product.

15. The method of claim 1 , wherein the peptide product comprising at least one cyclic imide group of formula (I) is lixisenatide having at least one cyclic imide group at position Asp(9).

16. The method of claim 1 , wherein the peptide product comprising at least one cyclic imide group of formula (I) is selected from [Asp(9)-H 2 O]-lixisenatide, [Asp(9)-H 2 O]-exendin-4, [Asp(9)-H 2 O]-liraglutide, and a salt or solvate thereof.

17. The method of claim 1 , wherein the least one cyclic imide group of formula (I) is at position Asp(9), Asp(16), Asp(15), Asp(21), Asn(32), or Asn(35) of the peptide product.

18. The method of claim 1 , wherein the peptide product comprising at least one cyclic imide group of formula (I) is selected from [Asp(9)-H 2 O]-lixisenatide, [Asp(9)-H 2 O]-exendin-4, [Asp(9)-H 2 O]-liraglutide, [Asp(16)-H 2 O]-GLP-1(7-36), [Asp(9)-H 2 O]-glucagon, [Asp(15)-H 2 O]-glucagon, [Asp(21)-H 2 O]-glucagon, [Asp(9)-H 2 O]-oxyntomodulin, [Asp(15)-H 2 O]-oxyntomodulin, [Asp(21)-H 2 O]-oxyntomodulin, [Asn(32)-NH 3 ]-oxyntomodulin, [Asn(34)-NH 3 ]-oxyntomodulin, [Asn(35)-NH 3 ]-oxyntomodulin, and a salt or solvate thereof.

Assignees

• Sanofi Aventis Deutschland

Inventors

• Henkel Bernd

Classifications

• C08G18/3846

  containing imide groups (C08G18/3821 takes precedence) · CPC title

• C07K14/605

  Glucagons · CPC title

• C07K1/042

  characterised by the nature of the carrier · CPC title

• C07K1/1077 Primary

  by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids · CPC title

• C07K1/006 Primary

  of peptides containing derivatised side chain amino acids · CPC title